GlassScriptPhysician profile
Hsiangkuo Yuan
NPI 1255711149
$44,350.51
in general payments reported to CMS, 2019-2025
26 companies · $17K in 2025
The $17K reported for 2025 was more than what 92% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $868 · 2020: $109 · 2021: $834 · 2022: $1,111 · 2023: $11K · 2024: $14K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $33K · Food and Beverage: $5,410 · Travel and Lodging: $2,594.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $33,425.00 |
| Food and Beverage | $5,409.66 |
| Travel and Lodging | $2,593.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $18,125.00 | 2023-2025 | Trufill |
| Pfizer INC. | $17,306.80 | 2023-2025 | |
| Abbvie INC. | $3,310.19 | 2019-2025 | Qulipta, Botox, Ubrelvy |
| Ipsen Innovation | $1,182.54 | 2023 | Dysport |
| Teva Pharmaceuticals USA, INC. | $942.35 | 2019-2025 | Ajovy, Austedo Xr, Austedo |
| Allergan, INC. | $809.66 | 2019-2021 | |
| Amgen INC. | $490.13 | 2019-2024 | Aimovig |
| Lilly USA, LLC | $488.43 | 2020-2025 | Emgality, Reyvow |
| Impel Pharmaceuticals INC. | $481.69 | 2022-2023 | Trudhesa |
| Axsome Therapeutics, INC. | $192.40 | 2024-2025 | Symbravo |
| Upsher-Smith Laboratories LLC | $172.29 | 2020-2023 | |
| Spr Therapeutics, INC | $154.47 | 2019-2021 | |
| Lundbeck LLC | $152.51 | 2023-2025 | Vyepti |
| Argenx US, INC. | $100.44 | 2023 | Vyvgart |
| Scilex Pharmaceuticals INC. | $85.37 | 2023-2024 | Ztlido |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $63.52 | 2022 | |
| Eisai INC. | $45.44 | 2023-2024 | |
| Collegium Pharmaceutical, INC. | $44.77 | 2022 | |
| Pfizer Corporation Hong Kong Limited | $42.95 | 2023 | |
| Novartis Pharmaceuticals Corporation | $39.44 | 2019 | |
| Amneal Pharmaceuticals LLC | $26.72 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $23.37 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $21.57 | 2021 | |
| Avanir Pharmaceuticals, INC. | $20.52 | 2019 | |
| Promius Pharma LLC | $15.22 | 2019 | |
| Zyla Life Sciences, INC. | $12.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hsiangkuo Yuan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.